252 related articles for article (PubMed ID: 17179698)
1. A patient with mixed type Evans syndrome: efficacy of rituximab treatment.
Park CY; Chung CH
J Korean Med Sci; 2006 Dec; 21(6):1115-6. PubMed ID: 17179698
[TBL] [Abstract][Full Text] [Related]
2. Consolidation treatment with rituximab induces complete and persistent remission of mixed type Evans syndrome.
Rodella E; Pacquola E; Bianchini E; Ramazzina E; Paolini R
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):315-8. PubMed ID: 18469554
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases.
Mantadakis E; Danilatou V; Stiakaki E; Kalmanti M
Am J Hematol; 2004 Nov; 77(3):303-10. PubMed ID: 15495242
[TBL] [Abstract][Full Text] [Related]
4. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of a patient with mixed warm and cold antibody mediated Evans syndrome and glucose intolerance.
Jubinsky PT; Rashid N
Pediatr Blood Cancer; 2005 Sep; 45(3):347-50. PubMed ID: 15704210
[TBL] [Abstract][Full Text] [Related]
6. Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome.
Carey EJ; Somaratne K; Rakela J
Rev Med Chil; 2011 Nov; 139(11):1484-7. PubMed ID: 22446656
[TBL] [Abstract][Full Text] [Related]
7. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
9. Successful use of rituximab in Evans syndrome and refractory immune thrombocytopenic purpura.
Kashif M; Qureshi A; Adil SN; Khurshid M
J Pak Med Assoc; 2010 Jan; 60(1):64-5. PubMed ID: 20055286
[TBL] [Abstract][Full Text] [Related]
10. Rituximab therapy in a patient with autoimmune hemolytic anemia and immune thrombocytopenia associated with chronic lymphocytic leukemia.
Aleem A
Ann Saudi Med; 2008; 28(5):382-5. PubMed ID: 18779631
[No Abstract] [Full Text] [Related]
11. Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab-based therapy in a chronic lymphocytic leukemia patient.
Gentile M; Lucia E; Iorio C; Vigna E; Mazzone C; Morelli R; Bisconte MG; Gentile C; Morabito F
Cancer Chemother Pharmacol; 2008 Sep; 62(4):741-3. PubMed ID: 18064461
[TBL] [Abstract][Full Text] [Related]
12. Successful use of rituximab in refractory idiopathic thrombocytopenic purpura in a patient with common variable immunodeficiency.
Al-Ahmad M; Al-Rasheed M; Al-Muhani A
J Investig Allergol Clin Immunol; 2010; 20(3):259-62. PubMed ID: 20635793
[TBL] [Abstract][Full Text] [Related]
13. Sustained remission of CIDP associated with Evans syndrome.
Knecht H; Baumberger M; Tobòn A; Steck A
Neurology; 2004 Aug; 63(4):730-2. PubMed ID: 15326255
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004).
Scheinberg M; Hamerschlak N; Kutner JM; Ribeiro AA; Ferreira E; Goldenberg J; Kiss MH; Chahade WH
Clin Exp Rheumatol; 2006; 24(1):65-9. PubMed ID: 16539821
[TBL] [Abstract][Full Text] [Related]
15. Rituximab therapy for childhood Evans syndrome.
Bader-Meunier B; Aladjidi N; Bellmann F; Monpoux F; Nelken B; Robert A; Armari-Alla C; Picard C; Ledeist F; Munzer M; Yacouben K; Bertrand Y; Pariente A; Chaussé A; Perel Y; Leverger G
Haematologica; 2007 Dec; 92(12):1691-4. PubMed ID: 18055994
[TBL] [Abstract][Full Text] [Related]
16. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.
Heidel F; Lipka DB; von Auer C; Huber C; Scharrer I; Hess G
Thromb Haemost; 2007 Feb; 97(2):228-33. PubMed ID: 17264951
[TBL] [Abstract][Full Text] [Related]
17. Rituximab treatment for relapsed autoimmune hemolytic anemia in Evans syndrome.
Galor A; O'Brien T
Int J Hematol; 2003 Nov; 78(4):335-6. PubMed ID: 14686491
[TBL] [Abstract][Full Text] [Related]
18. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J
Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
[TBL] [Abstract][Full Text] [Related]
19. Adult Evans syndrome: complete hematologic recovery with steroids and rituximab: a case report.
Santiago-Ríos KJ; Reyes O; Cruz A; Rodríguez-Pabón N; Cáceres W
Bol Asoc Med P R; 2010; 102(2):33-6. PubMed ID: 20939201
[TBL] [Abstract][Full Text] [Related]
20. [Anti-CD20 monoclonal antibody for the treatment of refractory autoimmune hemolytic anemia].
Wang L; Xu W; Li JY; Xie XY; Sheng RL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):425-8. PubMed ID: 17493362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
